These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32610327)

  • 1. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL; Lim A; Munns C; Simm PJ; Zacharin M
    Horm Res Paediatr; 2020; 93(2):108-118. PubMed ID: 32610327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne muscular dystrophy.
    Wood CL; Cheetham TD; Hollingsworth KG; Guglieri M; Ailins-Sahun Y; Punniyakodi S; Mayhew A; Straub V
    BMC Pediatr; 2019 Apr; 19(1):131. PubMed ID: 31023296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area.
    Wood CL; Hollingsworth KG; Hughes E; Punniyakodi S; Muni-Lofra R; Mayhew A; Mitchell RT; Guglieri M; Cheetham TD; Straub V
    Eur J Endocrinol; 2021 Jan; 184(1):67-79. PubMed ID: 33112266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy.
    Wood CL; Cheetham TD; Guglieri M; Bushby K; Owen C; Johnstone H; Straub V
    Neuropediatrics; 2015 Dec; 46(6):371-6. PubMed ID: 26408798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short stature and pubertal delay in Duchenne muscular dystrophy.
    Wood CL; Straub V; Guglieri M; Bushby K; Cheetham T
    Arch Dis Child; 2016 Jan; 101(1):101-6. PubMed ID: 26141541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL; Craven BC; McAdam LC; Biggar WD
    Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
    Dooley JM; Bobbitt SA; Cummings EA
    Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
    Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
    J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
    Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids.
    Loscalzo E; See J; Bharill S; Yousefzadeh N; Gough E; Wu M; Crane JL
    Osteoporos Int; 2024 Feb; 35(2):327-338. PubMed ID: 37872346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy.
    Wood CL; Page J; Foggin J; Guglieri M; Straub V; Cheetham TD
    Neuromuscul Disord; 2021 Dec; 31(12):1259-1265. PubMed ID: 34702655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.